Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cross-platform Data Analysis Reveals a Generic Gene Expression Signature for Microsatellite Instability in Colorectal Cancer

A. Pačínková, V. Popovici,

. 2019 ; 2019 (-) : 6763596. [pub] 20190317

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19034613

The dysfunction of the DNA mismatch repair system results in microsatellite instability (MSI). MSI plays a central role in the development of multiple human cancers. In colon cancer, despite being associated with resistance to 5-fluorouracil treatment, MSI is a favourable prognostic marker. In gastric and endometrial cancers, its prognostic value is not so well established. Nevertheless, recognising the MSI tumours may be important for predicting the therapeutic effect of immune checkpoint inhibitors. Several gene expression signatures were trained on microarray data sets to understand the regulatory mechanisms underlying microsatellite instability in colorectal cancer. A wealth of expression data already exists in the form of microarray data sets. However, the RNA-seq has become a routine for transcriptome analysis. A new MSI gene expression signature presented here is the first to be valid across two different platforms, microarrays and RNA-seq. In the case of colon cancer, its estimated performance was (i) AUC = 0.94, 95% CI = (0.90 - 0.97) on RNA-seq and (ii) AUC = 0.95, 95% CI = (0.92 - 0.97) on microarray. The 25-gene expression signature was also validated in two independent microarray colon cancer data sets. Despite being derived from colorectal cancer, the signature maintained good performance on RNA-seq and microarray gastric cancer data sets (AUC = 0.90, 95% CI = (0.85 - 0.94) and AUC = 0.83, 95% CI = (0.69 - 0.97), respectively). Furthermore, this classifier retained high concordance even when classifying RNA-seq endometrial cancers (AUC = 0.71, 95% CI = (0.62 - 0.81). These results indicate that the new signature was able to remove the platform-specific differences while preserving the underlying biological differences between MSI/MSS phenotypes in colon cancer samples.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034613
003      
CZ-PrNML
005      
20191010120954.0
007      
ta
008      
191007s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2019/6763596 $2 doi
035    __
$a (PubMed)31008109
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pačínková, Anna $u Faculty of Informatics, Masarykova Univerzita, Botanická 68a, Brno 602 00, Czech Republic. Faculty of Science, Research Centre for Toxic Compounds in the Environment, Masarykova Univerzita, Kamenice 5, Brno 625 00, Czech Republic.
245    10
$a Cross-platform Data Analysis Reveals a Generic Gene Expression Signature for Microsatellite Instability in Colorectal Cancer / $c A. Pačínková, V. Popovici,
520    9_
$a The dysfunction of the DNA mismatch repair system results in microsatellite instability (MSI). MSI plays a central role in the development of multiple human cancers. In colon cancer, despite being associated with resistance to 5-fluorouracil treatment, MSI is a favourable prognostic marker. In gastric and endometrial cancers, its prognostic value is not so well established. Nevertheless, recognising the MSI tumours may be important for predicting the therapeutic effect of immune checkpoint inhibitors. Several gene expression signatures were trained on microarray data sets to understand the regulatory mechanisms underlying microsatellite instability in colorectal cancer. A wealth of expression data already exists in the form of microarray data sets. However, the RNA-seq has become a routine for transcriptome analysis. A new MSI gene expression signature presented here is the first to be valid across two different platforms, microarrays and RNA-seq. In the case of colon cancer, its estimated performance was (i) AUC = 0.94, 95% CI = (0.90 - 0.97) on RNA-seq and (ii) AUC = 0.95, 95% CI = (0.92 - 0.97) on microarray. The 25-gene expression signature was also validated in two independent microarray colon cancer data sets. Despite being derived from colorectal cancer, the signature maintained good performance on RNA-seq and microarray gastric cancer data sets (AUC = 0.90, 95% CI = (0.85 - 0.94) and AUC = 0.83, 95% CI = (0.69 - 0.97), respectively). Furthermore, this classifier retained high concordance even when classifying RNA-seq endometrial cancers (AUC = 0.71, 95% CI = (0.62 - 0.81). These results indicate that the new signature was able to remove the platform-specific differences while preserving the underlying biological differences between MSI/MSS phenotypes in colon cancer samples.
650    _2
$a kolorektální nádory $x genetika $x patologie $7 D015179
650    _2
$a analýza dat $7 D000078332
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese u nádorů $x genetika $7 D015972
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a mikrosatelitní nestabilita $7 D053842
650    _2
$a mikrosatelitní repetice $x genetika $7 D018895
650    _2
$a prognóza $7 D011379
650    _2
$a nádory žaludku $x genetika $x patologie $7 D013274
650    _2
$a transkriptom $x genetika $7 D059467
655    _2
$a časopisecké články $7 D016428
700    1_
$a Popovici, Vlad $u Faculty of Science, Research Centre for Toxic Compounds in the Environment, Masarykova Univerzita, Kamenice 5, Brno 625 00, Czech Republic.
773    0_
$w MED00182164 $t BioMed research international $x 2314-6141 $g Roč. 2019, č. - (2019), s. 6763596
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31008109 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191010121413 $b ABA008
999    __
$a ok $b bmc $g 1451273 $s 1073163
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 2019 $c - $d 6763596 $e 20190317 $i 2314-6141 $m BioMed research international $n Biomed Res Int $x MED00182164
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...